A Phase 3 interventional study of Placebo and Teduglutide 0.05 mg/kg/d in Short Bowel Syndrome, sponsored by Shire. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 16 in phase 3, and was the 1st registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2004.
This study's enrollment of 84 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2004, is one of 17 in phase 3, and was the 1st registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).
Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation, and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.
The multicenter, double-blind, international Phase III trial will randomly assign approximately 80 patients to receive daily subcutaneous injections of 0.05 milligrams or 0.10 milligrams of teduglutide per kilogram of body weight, or a placebo. Dosing will continue for a period of six months. The primary endpoint in the study is a reduction in the use of intravenous feeding, which is often required to sustain life in patients with SBS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo injectable subcutaneously daily into the thigh or abdomen
Drug: Placebo
teduglutide 0.05 mg/kg/d
Drug: Teduglutide 0.05 mg/kg/d
teduglutide 0.1 mg/kg/d
Drug: Teduglutide 0.1 mg/kg/d
placebo injectable subcutaneously daily into thigh or abdomen
Drug page: Teduglutide
Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
Also known as: GATTEX
Drug page: Teduglutide
Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
Also known as: GATTEX
A Graded Response Score in Parenteral Nutrition (PN) Reduction
The intensity of the response relied on a reduction from Baseline in weekly parenteral nutrition (PN) volume (minimum reduction of 20% and a maximum of 100%). Duration of the response incorporated responses at Weeks(Wk) 16-20 and at Wk20-24. Zero (0 - lowest) assigned if \<20% reduction at Wk20-24 and reduction at Wk16-20 of \< 20%, 20-39%, or \>=40%. One (1) assigned if reduction of 20-39% at Wk20-24 but \< 20% at Wk16-20. Two(2) assigned if reductions of 40-99% at Wk20-24 AND \<20% at Wk16-20 OR 20-39% at Wk20-24 AND 20-39% at Wk16-20. Three (3) assigned if reductions of 100% at Wk20-24 AND \<20% at Wk16-20 OR 40-99% at Wk20-24 AND 20-39% at Wk16-20 OR 20-39% at Wk20-24 AND \>=40% at Wk16-20. Four (4) assigned if reductions of 100% at Wk20-24 AND 20-39% at Wk16-20 OR 40-99% at Wk20-24 AND \>=40% at Wk16-20.
Time frame: 6 months
Number of Subjects Achieving Binary Response at Week 20, Maintained at Week 24
An efficacy responder was defined as achieving at least a 20% reduction from Baseline to Week 20 and maintained at Week 24 in weekly actual PN infusion volume.
Time frame: 6 months of treatment
First subject was screened 25May2004 and last subject evaluations were completed on 06Jul2007.
| Milestone | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d |
|---|---|---|---|
| Started | 16 | 35 | 33 |
| Received treatment | 16 | 35 | 32 |
| Completed | 15 | 27 | 29 |
| Not completed | 1 | 8 | 4 |
| Withdrew: Adverse event | 1 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 |
| Withdrew: Randomized but not dosed | 0 | 0 | 1 |
The intensity of the response relied on a reduction from Baseline in weekly parenteral nutrition (PN) volume (minimum reduction of 20% and a maximum of 100%). Duration of the response incorporated responses at Weeks(Wk) 16-20 and at Wk20-24. Zero (0 - lowest) assigned if \<20% reduction at Wk20-24 and reduction at Wk16-20 of \< 20%, 20-39%, or \>=40%. One (1) assigned if reduction of 20-39% at Wk20-24 but \< 20% at Wk16-20. Two(2) assigned if reductions of 40-99% at Wk20-24 AND \<20% at Wk16-20 OR 20-39% at Wk20-24 AND 20-39% at Wk16-20. Three (3) assigned if reductions of 100% at Wk20-24 AND \<20% at Wk16-20 OR 40-99% at Wk20-24 AND 20-39% at Wk16-20 OR 20-39% at Wk20-24 AND \>=40% at Wk16-20. Four (4) assigned if reductions of 100% at Wk20-24 AND 20-39% at Wk16-20 OR 40-99% at Wk20-24 AND \>=40% at Wk16-20.
| participants | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d |
|---|---|---|---|
| 0 (No Response) | 15 | 19 | 24 |
| 1 | 0 | 6 | 2 |
| 2 | 1 | 6 | 4 |
| 4 | 0 | 2 | 2 |
| 5 (No longer need PN) | 0 | 2 | 0 |
An efficacy responder was defined as achieving at least a 20% reduction from Baseline to Week 20 and maintained at Week 24 in weekly actual PN infusion volume.
| participants | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d |
|---|---|---|---|
| Responder | 1 (0 to 18.1) | 16 (29.2 to 62.2) | 8 (10.0 to 40.0) |
| Non-Responder | 15 (0 to 0) | 19 (0 to 0) | 24 (0 to 0) |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 5/16 (31.3%) | 15/16 (93.8%) |
| Teduglutide 0.05 mg/kg/d | — | 13/35 (37.1%) | 33/35 (94.3%) |
| Teduglutide 0.1 mg/kg/d | — | 11/32 (34.4%) | 31/32 (96.9%) |
| Event | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d |
|---|---|---|---|
| Catheter related complicationGeneral disorders | 3/16 | 0/35 | 3/32 |
| Catheter sepsisInfections and infestations | 1/16 | 3/35 | 4/32 |
| Catheter bacteraemiaInfections and infestations | 1/16 | 1/35 | 0/32 |
| Device failureInjury, poisoning and procedural complications | 1/16 | 0/35 | 1/32 |
| Eye InjuryInjury, poisoning and procedural complications | 1/16 | 0/35 | 0/32 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 0/35 | 0/32 |
| Intervertebral discitisMusculoskeletal and connective tissue disorders | 1/16 | 0/35 | 0/32 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/16 | 0/35 | 0/32 |
| PyrexiaGeneral disorders | 0/16 | 2/35 | 0/32 |
| Catheter site infectionInfections and infestations | 0/16 | 2/35 | 0/32 |
| Event | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/16 | 5/35 | 10/32 |
| Abdominal painGastrointestinal disorders | 2/16 | 7/35 | 9/32 |
| HeadacheNervous system disorders | 1/16 | 9/35 | 7/32 |
| Injection site bruisingGeneral disorders | 0/16 | 1/35 | 7/32 |
| Catheter related complicationsGeneral disorders | 3/16 | 1/35 | 3/32 |
| Injection site erythemaGeneral disorders | 0/16 | 1/35 | 6/32 |
| VomitingGastrointestinal disorders | 2/16 | 4/35 | 6/32 |
| Urinary tract infectionInfections and infestations | 3/16 | 3/35 | 5/32 |
| abdominal distensionGastrointestinal disorders | 0/16 | 6/35 | 3/32 |
| NasopharyngitisInfections and infestations | 2/16 | 6/35 | 5/32 |
84 subjects were initially randomized; however, one subject never received study therapy. As a result, the total participant who started flow period is 83.
| Age, Continuous(years) | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d | Total |
|---|---|---|---|---|
| Mean | 49.4 ± 15.1 | 47.1 ± 14.2 | 50.3 ± 14.0 | 48.8 ± 14.2 |
| Age, Customized(Participants) | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d | Total |
|---|---|---|---|---|
| < 35 years | 3 | 7 | 5 | 15 |
| 35-44 years | 2 | 5 | 4 | 11 |
| 45 - 54 years | 3 | 12 | 10 | 25 |
| > 55 years | 8 | 11 | 13 | 32 |
| Sex: Female, Male(Participants) | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d | Total |
|---|---|---|---|---|
| Female | 9 | 18 | 19 | 46 |
| Male | 7 | 17 | 13 | 37 |
| Region of Enrollment(Participants) | Placebo | Teduglutide 0.05 mg/kg/d | Teduglutide 0.1 mg/kg/d | Total |
|---|---|---|---|---|
| Belgium | 1 | 1 | 0 | 2 |
| Canada | 1 | 2 | 5 | 8 |
| Denmark | 2 | 3 | 3 | 8 |
| France | 2 | 5 | 2 | 9 |
| Germany | 0 | 0 | 2 | 2 |
| Netherlands | 0 | 4 | 1 | 5 |
| Poland | 3 | 6 | 8 | 17 |
| United Kingdom | 0 | 3 | 1 | 4 |
| United States | 7 | 11 | 10 | 28 |
Ran from May 2004 to primary completion in Jul 2007, 37 months.
Results were first posted in Jul 2013, 6 years after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 37 months is close to that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide